ARTICLE

AN OVERVIEW ON THE ONGOING CLINICAL TRIALS OF COVID19 VACCINES

  1. HOME
  2. ARTICLE

05 Pages : 39-48

http://dx.doi.org/10.31703/giidr.2020(V-I).05      10.31703/giidr.2020(V-I).05      Published : Dec 2020

An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines

Abstract

    COVID-19 has posed a great threat to mankind, there is a dire need to introduce a vaccine to combat this global pandemic. Several vaccines are underway to complete their phase 3 clinical trials. This article highlights events surrounding the ongoing clinical trials of vaccines effective against COVID-19, and different procedures and formalities the vaccine will have to endure to get EUA. Clinical trials are discussed stepwise along with the clinical endpoint desired at the end of these trials. In line with antimicrobial resistance, vaccine resistance has also emerged in this era and needs focused consideration, and the probability of development of resistance in these vaccines is discussed. This article specifically covers the latest research reporting clinical efficacy, safety profile, and adverse events following the administration of doses to patients and concerns regarding the rushed approval of vaccines. Four vaccines have been discussed in detail; BNT162b2, mRNA-1273, Sputnik V, ChAdOx1.

    COVID-19, SARS-CoV-2, Vaccine, Clinical Trial, Vaccine Resistance, Clinical Endpoint

    (1) Syeda Komal Fatima
    Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (2) Ameena Tur Rasool
    Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (3) Ayesha Sabir
    Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (4) Gul Shahnaz
    Chairperson, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.(Corresponding Author)
Fulltext PDF

References

  • Burki, T. K. (2020). The Russian vaccine for COVID- 19. The Lancet Respiratory Medicine, 8(11), e85- e86.
  • Caddy, S. (2020). Developing a vaccine for covid-19. 369, m1790. doi:10.1136/bmj.m1790 & BMJ
  • Callaway, E. (2020). OXFORD COVID VACCINE RESULTS PUZZLE SCIENTISTS. Nature, 588.
  • Center for Disease Control. (2020, December 13th.). Ensuring COVID-19 Vaccines Work. www.cdc.gov/coronavirus/2019- ncov/vaccines/effectiveness/.
  • Corum, J., Grady, D., Wee, S. L., & Zimmer, C. (2020). Coronavirus vaccine tracker. The New York Times, 5.
  • Chakraborty, R., & Parvez, S. (2020). COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. Biochemical Pharmacology, 114184
  • Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W. C., Wang, C. B., & Bernardini, S. (2020). The COVID- 19 pandemic. Critical Reviews in Clinical Laboratory Sciences, 57(6), 365-388.
  • Cohen, J. (2020). Vaccine designers take first shots at COVID-19.
  • Corey, L., Mascola, J. R., Fauci, A. S., & Collins, F. S. (2020). A strategic approach to COVID-19 vaccine R&D. Science, 368(6494), 948-950.
  • Cyranoski, D. (2020). Why emergency COVID-vaccine approvals pose a dilemma for scientists. Nature, 588, 18-19.
  • De Soto, J. A., & DSSc, F. A. I. C. (2020). Evaluation of the Moderna, Pfizer/biontech, Astrazeneca/oxford and Sputnik V Vaccines for COVID-19.
  • Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., ... & Dold, C. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 396(10249), 467-478.
  • Kennedy, D. A., & Read, A. F. (2020). Monitor for COVID-19 vaccine resistance evolution during clinical trials. PLoS Biology, 18(11), e3001000.
  • Knoll, M. D., & Wonodi, C. (2020). Oxford- AstraZeneca COVID-19 vaccine efficacy. The Lancet
  • Le, T. T., Cramer, J. P., Chen, R., & Mayhew, S. (2020). Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov, 19(10), 667-8.
  • Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 vaccines at pandemic speed. New England Journal of Medicine, 382(21), 1969-1973.
  • Lythgoe, M. P., & Middleton, P. (2020). Ongoing clinical trials for the management of the COVID- 19 pandemic. Trends in Pharmacological Sciences.
  • Mehrotra, D. V., Janes, H. E., Fleming, T. R., Annunziato, P. W., Neuzil, K. M., Carpp, L. N., ... & Donnell, D. (2020). Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials. Annals of internal medicine.
  • Moderna. (2020, November 16th). Moderna's COVID- 19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study.
  • Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. P., ... & Li, P. (2020). Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medrxiv
  • Pang, J., Wang, M. X., Ang, I. Y. H., Tan, S. H. X., Lewis, R. F., Chen, J. I. P., ... & Ng, X. Y. (2020). Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. Journal of clinical medicine, 9(3), 623.
  • Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Bailey, R. (2020). Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. New England Journal of Medicine.
  • Shafi, M., Liu, J., & Ren, W. (2020). Impact of COVID- 19 pandemic on micro, small, and medium-sized Enterprises operating in Pakistan. Research in Globalization, 2, 100018.
  • Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research.
  • Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., ... & Steinmetz, N. F. (2020). COVID-19 vaccine development and a potential nanomaterial path forward. Nature nanotechnology, 15(8), 646-655.
  • Singh, J. A., & Upshur, R. E. (2020). The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. The Lancet Infectious Diseases.
  • Thorp, H. H. (2020). A dangerous rush for vaccines. Science. pp. 885-885
  • Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., ... & Bibi, S. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet
  • Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020). The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech, 21(6), 1-12
  • Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., ... & Chen, X. (2020). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases.
  • Zhu, F. C., Guan, X. H., Li, Y. H., Huang, J. Y., Jiang, T., Hou, L. H., ... & Wu, S. P. (2020). Immunogenicity an safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 396(10249), 479-488.

Cite this article

APA

    APA : Fatima, S. K., Rasool, A. T., & Sabir, A. (2020). An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines. Global Immunological & Infectious Diseases Review, V(I), 39-48. https://doi.org/10.31703/giidr.2020(V-I).05

CHICAGO

    CHICAGO : Fatima, Syeda Komal, Ameena Tur Rasool, and Ayesha Sabir. 2020. "An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines." Global Immunological & Infectious Diseases Review, V (I): 39-48 doi: 10.31703/giidr.2020(V-I).05

HARVARD

    HARVARD : FATIMA, S. K., RASOOL, A. T. & SABIR, A. 2020. An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines. Global Immunological & Infectious Diseases Review, V, 39-48.

MHRA

    MHRA : Fatima, Syeda Komal, Ameena Tur Rasool, and Ayesha Sabir. 2020. "An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines." Global Immunological & Infectious Diseases Review, V: 39-48

MLA

    MLA : Fatima, Syeda Komal, Ameena Tur Rasool, and Ayesha Sabir. "An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines." Global Immunological & Infectious Diseases Review, V.I (2020): 39-48 Print.

OXFORD

    OXFORD : Fatima, Syeda Komal, Rasool, Ameena Tur, and Sabir, Ayesha (2020), "An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines", Global Immunological & Infectious Diseases Review, V (I), 39-48

TURABIAN

    TURABIAN : Fatima, Syeda Komal, Ameena Tur Rasool, and Ayesha Sabir. "An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines." Global Immunological & Infectious Diseases Review V, no. I (2020): 39-48. https://doi.org/10.31703/giidr.2020(V-I).05